Literature DB >> 21586096

Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.

Anders Pryds1, Michael Larsen.   

Abstract

PURPOSE: To evaluate the effect of verteporfin photodynamic treatment (PDT) on choroidal thickness in patients with central serous chorioretinopathy (CSC).
METHODS: Choroidal thickness was measured with enhanced depth imaging- optical coherence tomography (EDI-OCT) before and after verteporfin PDT (full-dose verteporfin, half-light dose) in 16 eyes in 16 patients with serous detachment of the fovea secondary to extrafoveal angiographic fluorescein leakage. Treatment was confined to the area of leakage, whereas choroidal thickness before and after treatment was assessed over a larger area of the fundus using OCT.
RESULTS: Complete resolution of the serous detachment was seen in all 16 eyes within 1 month of extrafoveal PDT, while choroidal thickness in the area where PDT was applied decreased from 407 μm [mean; 95% confidence interval (CI(95) ) 356-458 μm] to 349 μm (mean; CI(95) 300-399 μm; p < 0.0001), and subfoveal choroidal thickness was reduced from 421 μm (mean; CI(95) 352-489 μm) to 346 μm (mean; CI(95) 278-414 μm; p = 0.0001). Initially, subfoveal choroidal thickness was significantly increased in the treated eye compared with the healthy fellow eye (mean 324 μm; CI(95) 273-376 μm; p = 0.0003), but after treatment, the difference was not significant. DISCUSSION: Photodynamic therapy of active CSC was followed by choroidal thickness reduction, not only locally but also at considerable distance from the treated area. Thus, the process that causes choroidal thickening in CSC appears to spread laterally within the choroid.
© 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21586096     DOI: 10.1111/j.1755-3768.2011.02157.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  14 in total

1.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

Review 2.  A comprehensive review of diagnostic imaging technologies to evaluate the retina and the optic disk.

Authors:  Asima Bajwa; Rabia Aman; Ashvini K Reddy
Journal:  Int Ophthalmol       Date:  2015-06-05       Impact factor: 2.031

3.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

4.  A novel and faster method of manual grading to measure choroidal thickness using optical coherence tomography.

Authors:  K X Cheong; L W Lim; K Z Li; C S Tan
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 5.  Choroidal imaging using spectral-domain optical coherence tomography.

Authors:  Caio V Regatieri; Lauren Branchini; James G Fujimoto; Jay S Duker
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

Review 6.  Optical coherence tomography--current and future applications.

Authors:  Mehreen Adhi; Jay S Duker
Journal:  Curr Opin Ophthalmol       Date:  2013-05       Impact factor: 3.761

7.  The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.

Authors:  Dong Yoon Kim; Soo Geun Joe; Sung Jae Yang; Joo Yong Lee; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2015-05-20

8.  Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study.

Authors:  Fuminori Haga; Ruka Maruko; Chiaki Sato; Keiko Kataoka; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

9.  Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy.

Authors:  Carl Schubert; Anders Pryds; Shemin Zeng; Yajing Xie; K Bailey Freund; Richard F Spaide; John C Merriam; Irene Barbazetto; Jason S Slakter; Stanley Chang; Inger C Munch; Arlene V Drack; Jasmine Hernandez; Suzanne Yzer; Joanna E Merriam; Allan Linneberg; Michael Larsen; Lawrence A Yannuzzi; Robert F Mullins; Rando Allikmets
Journal:  Hum Mutat       Date:  2014-07       Impact factor: 4.700

10.  Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.

Authors:  Elon H C van Dijk; Greet Dijkman; Camiel J F Boon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.